GILD Quote, Financials, Valuation and Earnings

Biogen has a net margin of 19.72% compared to Gilead Sciences's net margin of 9.89%. Gilead Sciences's return on equity of 32.29% beat Biogen's return on equity of 9.11%.

Gilead Sciences has a consensus price target of $115.04, signalling upside risk potential of 18.71%. On the other hand Biogen has an analysts' consensus of $172.25 which suggests that it could grow by 45.76%. Given that Biogen has higher upside potential than Gilead Sciences, analysts believe Biogen is more attractive than Gilead Sciences.

Gilead Sciences has a beta of 0.263, which suggesting that the stock is 73.697% less volatile than S&P 500. In comparison Biogen has a beta of 0.125, suggesting its less volatile than the S&P 500 by 87.479%.

Gilead Sciences has a quarterly dividend of $0.79 per share corresponding to a yield of 3.2%. Biogen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Gilead Sciences pays 816.25% of its earnings as a dividend. Biogen pays out -- of its earnings as a dividend.

Gilead Sciences quarterly revenues are $6.7B, which are larger than Biogen quarterly revenues of $2.4B. Gilead Sciences's net income of $1.3B is higher than Biogen's net income of $240.5M. Notably, Gilead Sciences's price-to-earnings ratio is 20.40x while Biogen's PE ratio is 11.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Gilead Sciences is 4.25x versus 1.76x for Biogen. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of 19.72% compared to Gilead Sciences's net margin of 50.24%. Gilead Sciences's return on equity of 32.29% beat Johnson & Johnson's return on equity of 30.18%.

Gilead Sciences has a consensus price target of $115.04, signalling upside risk potential of 18.71%. On the other hand Johnson & Johnson has an analysts' consensus of $170.19 which suggests that it could grow by 10.36%. Given that Gilead Sciences has higher upside potential than Johnson & Johnson, analysts believe Gilead Sciences is more attractive than Johnson & Johnson.

Gilead Sciences has a beta of 0.263, which suggesting that the stock is 73.697% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.425, suggesting its less volatile than the S&P 500 by 57.471%.

Gilead Sciences has a quarterly dividend of $0.79 per share corresponding to a yield of 3.2%. Johnson & Johnson offers a yield of 3.22% to investors and pays a quarterly dividend of $1.24 per share. Gilead Sciences pays 816.25% of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Gilead Sciences's is not.

Gilead Sciences quarterly revenues are $6.7B, which are smaller than Johnson & Johnson quarterly revenues of $21.9B. Gilead Sciences's net income of $1.3B is lower than Johnson & Johnson's net income of $11B. Notably, Gilead Sciences's price-to-earnings ratio is 20.40x while Johnson & Johnson's PE ratio is 17.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Gilead Sciences is 4.25x versus 4.19x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 19.72% compared to Gilead Sciences's net margin of -907.48%. Gilead Sciences's return on equity of 32.29% beat Moderna's return on equity of -29.23%.

Gilead Sciences has a consensus price target of $115.04, signalling upside risk potential of 18.71%. On the other hand Moderna has an analysts' consensus of $46.96 which suggests that it could grow by 93.66%. Given that Moderna has higher upside potential than Gilead Sciences, analysts believe Moderna is more attractive than Gilead Sciences.

Gilead Sciences has a beta of 0.263, which suggesting that the stock is 73.697% less volatile than S&P 500. In comparison Moderna has a beta of 1.995, suggesting its more volatile than the S&P 500 by 99.542%.

Gilead Sciences has a quarterly dividend of $0.79 per share corresponding to a yield of 3.2%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Gilead Sciences pays 816.25% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Gilead Sciences quarterly revenues are $6.7B, which are larger than Moderna quarterly revenues of $107M. Gilead Sciences's net income of $1.3B is higher than Moderna's net income of -$971M. Notably, Gilead Sciences's price-to-earnings ratio is 20.40x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Gilead Sciences is 4.25x versus 3.01x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of 19.72% compared to Gilead Sciences's net margin of 23.33%. Gilead Sciences's return on equity of 32.29% beat Vertex Pharmaceuticals's return on equity of -6.04%.

Gilead Sciences has a consensus price target of $115.04, signalling upside risk potential of 18.71%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $500.30 which suggests that it could grow by 17.72%. Given that Gilead Sciences has higher upside potential than Vertex Pharmaceuticals, analysts believe Gilead Sciences is more attractive than Vertex Pharmaceuticals.

Gilead Sciences has a beta of 0.263, which suggesting that the stock is 73.697% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.511, suggesting its less volatile than the S&P 500 by 48.928%.

Gilead Sciences has a quarterly dividend of $0.79 per share corresponding to a yield of 3.2%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Gilead Sciences pays 816.25% of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

Gilead Sciences quarterly revenues are $6.7B, which are larger than Vertex Pharmaceuticals quarterly revenues of $2.8B. Gilead Sciences's net income of $1.3B is higher than Vertex Pharmaceuticals's net income of $646.3M. Notably, Gilead Sciences's price-to-earnings ratio is 20.40x while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Gilead Sciences is 4.25x versus 9.92x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.